Free CME and CE Credits – General Information
The NIAAA Core Resource on Alcohol CME/CE activities are intended for healthcare professionals including physicians, physician assistants, nurses, clinical, psychologists, and pharmacists.
Joint Accreditation Statement
In support of improving patient care, CME/CE activities offered have been planned and implemented by the Postgraduate Institute for Medicine and NIAAA. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learners who complete all 14 NIAAA Core Resource on Alcohol articles can receive a maximum of 10.75 credits. The table below indicates the credit amount that can be earned for each individual article. Articles can be completed in any order and free CME/CE credit can be earned for as many or as few articles as desired. CME University keeps a log of articles completed for credit. To view the course history, login to CME University, then under the “User Menu,” click on “My History” to see the date of participation, course title, post-test results, and credits earned.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 10.75 AMA PRA Category 1 Credit(s)™.
An American Board of Addiction Medicine (ABAM) Recognized Activity: This course is a recognized activity for ABAM Diplomates enrolled in the Transitional Continuous Certification Program (TraCC). This course has been recognized by ABAM. Physicians enrolled in ABAM TraCC can apply a maximum of 10.75 AMA PRA Category 1 Credits™ for completing The Healthcare Professional's Core Resource on Alcohol.
Continuing Physician Assistant Education
The Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for a maximum of 10.75 AAPA Category 1 CME credits. Approval is valid until PAs should only claim credit commensurate with the extent of their participation.
Continuing Nursing Education
The maximum number of hours awarded for Continuing Nursing Education activities offered is 10.75 contact hours.
Continuing Pharmacy Education
The Postgraduate Institute for Medicine designates continuing education activities offered for a maximum of 10.75 contact hour(s) (1.075 CEUs) of the Accreditation Council for Pharmacy Education.
Continuing Psychologist Education
Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This program offers a maximum of 10.75 continuing education credits for psychologists.
|Core Topic||Article Title||Credit Total||Activity UAN|
|1||The Basics: Defining How Much Alcohol is Too Much||0.75||JA4008162-9999-22-159-H01-P Type of Activity: Knowledge|
|2||Risk Factors: Varied Vulnerability to Alcohol-Related Harm||0.75||JA4008162-9999-22-162-H01-P Type of Activity: Knowledge|
|3||Neuroscience: The Brain in Addiction and Recovery||0.75||JA4008162-9999-22-163-H01-P Type of Activity: Knowledge|
|4||Stigma: Overcoming a Pervasive Barrier to Optimal Care||0.75||JA4008162-9999-22-164-H01-P Type of Activity: Knowledge|
|5||Medical Complications: Common Alcohol-Related Concerns||1.00||JA4008162-9999-22-165-H01-P Type of Activity: Knowledge|
|6||Alcohol-Medication Interactions: Potentially Dangerous Mixes||0.75||JA4008162-9999-22-166-H01-P Type of Activity: Knowledge|
|7||Mental Health Issues: Alcohol Use Disorder and Common Co-occurring Conditions||0.75||JA4008162-9999-22-167-H01-P Type of Activity: Knowledge|
|8||Alcohol Use Disorder: From Risk to Diagnosis to Recovery||0.75||JA4008162-9999-22-168-H01-P Type of Activity: Knowledge|
|9||Screen and Assess: Use Quick, Effective Methods||0.75||JA4008162-9999-22-169-H01-P Type of Activity: Knowledge|
|10||Conduct a Brief Intervention: Build Motivation and a Plan for Change||0.75||JA4008162-9999-22-170-H01-P Type of Activity: Knowledge|
|11||Recommend Evidence-Based Treatment: Know the Options||0.75||JA4008162-9999-22-171-H01-P Type of Activity: Knowledge|
|12||Make Referrals: Connect Patients to Alcohol Treatment That Meets Their Needs||0.75||JA4008162-9999-22-172-H01-P Type of Activity: Knowledge|
|13||Support Recovery: It’s a Marathon, Not a Sprint||0.75||JA4008162-9999-22-173-H01-P Type of Activity: Knowledge|
|14||Promote Practice Change: Take Manageable Steps Toward Better Care||0.75||JA4008162-9999-22-174-H01-P Type of Activity: Knowledge|
Disclosure of Financial Relationships
The Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The following financial relationships have been reported to Postgraduate Institute for Medicine (PIM). PIM has evaluated, identified, and mitigated any potential conflict of interest. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the education.
Dr. Michael Charness reports he is a stock shareholder of Pfizer.
Dr. H. Westley Clark discloses Speakers Bureau/Honorarium for non-CME from Indivior.
Dr. Zhigang (Peter) Gao discloses that he is a stock shareholder of Cassava, Geron and Moderna.
Dr. Deborah Hasin reports contracted research with Syneos Health.
Dr. John Krystal reports that he receives consulting fees from Aptinyx, Inc., Atai Life Sciences, Biogen Idec MA, Bionomics, Limited (Australia), Boehringer Ingelheim International, Cadent Therapeutics, Inc., Clexio Bioscience, Ltd., COMPASS Pathways, Limited, United Kingdom, Concert Pharmaceuticals Inc., Epiodyne Inc., EpiVario Inc., Greenwich Biosciences Inc., Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc., Takeda Industries and Taisho Pharmaceutical Co., Ltd. He is on the Board of Directors with Freedom Biosciences, Inc. Dr. Krystal is on the Scientific Advisory Board with Biohaven Pharmaceuticals, BioXcel Therapeutics, Inc. (Clinical Advisory Board), Cadent Therapeutics, Inc. (Clinical Advisory Board), Cerevel Therapeutics, LLC, Delix Therapeutics, Inc., EpiVario, Inc., Eisai, Inc., Jazz Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, PsychoGenics, Inc., Neumora Therapeutics, Inc., Tempero Bio, Inc., and Terran Biosciences, Inc. He reports he is a stock shareholder of Biohaven Pharmaceuticals, Sage Pharmaceuticals, and Spring Care Inc. Dr. Krystal discloses that he receives patent royalties from Biohaven Pharmaceuticals and Janssen Pharmaceuticals. He reports receiving research support from AstraZeneca Pharmaceuticals, Novartis, and Cerevel.
Dr. Evette Ludman discloses she is a stock share holder of Merck.
Dr. Barbara Mason reports consulting fees from Imbrium Theraputics. She is a stock share holder with Awakn Life Sciences Corporation.
Dr. Mack Mitchell discloses that he receives consulting fees from Mallinckrodt and Prodigy. He is a stock shareholder of Abbvie, Amygdala, Sunhydrogen and Moderna.
Dr. Olivier George discloses that he receives patent royalties from Cessation Therapeutics.
Dr. Patricia Powell reports she is a stock shareholder of Pfizer.
Dr. Arun Sanyal discloses that he receives patent royalties from Sanyal Bio. He receives consulting fees from Akero, Alnylam, Amgen, AstraZeneca, Blade, Boehringer Ingelheim, Bristol Myers Squibb, Enyo, Genentech, Gilead, Glympse, Histoindex, Intercept, Lilly, Madrigal, Mallinckrodt, Merck, Novo Nordisk, Path AI, Pfizer, Pliant, Poxel, Regeneron, Rivus, Salix, Siemens, Surrozen, Tern, Thera Technologies, Valeant, and Zydus. He is a stock shareholder of Durect, Exhalenz, Genfit, Hemoshear, and Indalo and Sanyal Bio.
Dr. Schatzberg discloses that he receives consulting fees from Alto, ANeuroTech, Axsome, Boehringer-Ingelheim, Bracket, Cambridge Health Partners, Compass, Delpor, EMA, Jazz, McKinsey, Myriad Genetics, NeuraWell, Otsuka, Owl Insights, Sage, Schwabe, Signant, Skyland Trail, and Tris. He is stock shareholder of Alto, Corcept (co-founder), Delpor, Epiodyne, Intersect ENT, Madrigal, Nesos, NeuraWell, Owl Insights, Seattle Genetics, Titan, and Xhale.
Dr. Vijay Shah reports that he receives consulting fees from Ambys Medicines, Durect Corporation, HepaRegeniX, Novartis Pharma AG, Akaza Bioscience Ltd., AgomAb Therapeutics, Generon Shangai, Intercept Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, and Surrozen.
Disclosure of Unlabeled Use
All CME/CE activities may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activities are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in the CME/CE activities are not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.